Sotatercept effect on heart and lung imaging for pulmonary hypertension
Part of Lungs & breathing clinical trials.
This trial tests how a new medication, sotatercept, affects the heart and lungs in people with pulmonary arterial hypertension (PAH). Using a special scan, the study looks at how the drug changes the blood vessels and heart over time to see if it helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have pulmonary arterial hypertension (PAH) of a specific type (idiopathic, inherited, drug-induced, connective tissue-related, or a simple heart defect repaired over a year ago).
- You must be on at least two PAH medications (background therapy).
- Your symptoms must be mild to moderate (WHO class II or III).
- You must be starting treatment with sotatercept.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.